Akums Drugs & Pharmaceuticals Ltd announced robust results for Q3 FY26, reporting a 16.5% YoY increase in Total Income, reaching ₹1,194 crore. EBITDA grew by an impressive 33.3% YoY to ₹181 crore. The CDMO segment remained the primary revenue driver, contributing 79.0% of the total income. The company noted strong volume growth, improved operating leverage, and steady ramp-up of new facilities during the quarter.
Q3 FY26 and 9MFY26 Earnings Overview
Akums Drugs & Pharmaceuticals Ltd reported positive results for the quarter ending December 31, 2025 (Q3 FY26), characterized by strong execution across key segments. The management highlighted a healthy operating performance driven by strong volumes in the Contract Development and Manufacturing Organization (CDMO) business, which saw topline growth exceeding 16%.
Consolidated Financial Performance (Q3 FY26)
The consolidated results showcase significant year-over-year improvements:
- Total Income: ₹1,194 crore (up 16.5% YoY).
- EBITDA: ₹181 crore (up 33.3% YoY).
- PAT: ₹68 crore (up 2.1% YoY).
On an operating basis (excluding one-time impact of New Labour codes), Revenue stood at ₹1,160 crore (up 14.8% YoY), with EBITDA growing 21.0% YoY to ₹147 crore.
Segmental Contribution in Q3 FY26
The business breakdown highlights the continued dominance of the CDMO vertical:
- CDMO: 79.0% of Q3 FY26 revenue.
- Domestic Branded Formulation: 9.9%.
- API: 4.7%.
- International Branded Formulation: 4.3%.
- Trade Generics: 2.1%.
Nine-Month Performance (9MFY26)
For the first nine months of FY26, the company recorded Total Income of ₹3,295 crore (up 6.4% YoY). While Adj. PAT saw a slight decline of 8.0% YoY to ₹175 crore, Adjusted EBITDA increased by 15.6% YoY to ₹464 crore.
Key Operational Drivers
The strong performance was attributed to several key drivers:
- Volume Growth: Akums witnessed double-digit volume growth, even as Indian Marketing Practice (IPM) volumes grew moderately at 1.2%.
- Capacity Utilization: Overall capacity utilization improved to 47%, supported by steady ramp-up of new facilities.
- Exports: Branded exports more than doubled Quarter-on-Quarter (QoQ).
- API Pressure: API prices remained soft but showed initial signs of stabilization.
Focus on Global Expansion and Quality
Progress continues on strategic international projects. The European CDMO project is on track to commence supplies in FY 28, following the receipt of EUGMP certification for the oral liquids’ facility. Furthermore, Plant 1 renewed its EUGMP certification, underscoring the commitment to global quality manufacturing standards.
Company Legacy and R&D Focus
The presentation reiterated Akums’ two-decade legacy, spanning from the establishment of its first solid dosage plant in 2004 to its listing on NSE and BSE in the 2022-26 period. The company continues to invest heavily in R&D, showcasing various Differentiated Dosage Forms (such as Tablet In Tablet and Lyophilized Vials) and numerous Innovative In-house Technologies like FAST ABSOL, Solphilic, and EntroSeal.
Source: BSE
